or Try an Advanced Search...

    Treatment Of Acute Myeloid Leukemia Stocks List

    Symbol Grade Name % Change
    HCWB C HCW Biologics Inc. 8.51
    SLS D SELLAS Life Sciences Group, Inc. -4.10
    PYXS D Pyxis Oncology, Inc. -9.52
    FBIO F Fortress Biotech, Inc. 2.55
    CGEM F Cullinan Management, Inc. 2.62
    BLRX F BioLineRx Ltd. -13.98
    APTO F Aptose Biosciences, Inc. -22.13
    TCBP F TC BioPharm (Holdings) plc -0.94
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Acute Myeloid Leukemia Clinical Medicine Biopharmaceutical Cancer Medicine Solid Tumors Biotechnology Immunotherapy Cancer Treatment Immune System Immunology Immunotherapies Oncology Antineoplastic Drugs Autoimmune Disease Cancer Immunotherapy Cell Therapy Clinical Development Hematologic Malignancies Monoclonal Antibody

    Related ETFs - A few ETFs which own one or more of the above listed Treatment Of Acute Myeloid Leukemia stocks.

    Symbol Grade Name Weight
    CNCR F Loncar Cancer Immunotherapy ETF 1.2
    CANC F Tema Oncology ETF 0.83
    BBC F Virtus LifeSci Biotech Clinical Trials ETF 0.55
    HAPS B Harbor Corporate Culture Small Cap ETF 0.27
    IWC B iShares Microcap ETF 0.26
    View all Treatment Of Acute Myeloid Leukemia ETFs...
    Compare ETFs
    Compare BBC to IWC Compare CNCR to HAPS Compare HAPS to IWC

        Treatment Of Acute Myeloid Leukemia Stocks Recent News

        Date Stock Title
        Nov 22 APTO S&P 500 Moves Higher; Intuit Shares Fall Following Q1 Results
        Nov 22 BLRX BioLineRx Q3 2024 Earnings Preview
        Nov 22 APTO Aptose Biosciences to sell 40M shares at $0.20 in public offering
        Nov 22 APTO Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering
        Nov 22 BLRX BioLineRx, Ayrmid enter license agreement for motixafortide through Gamida Cell
        Nov 21 PYXS Nasdaq Edges Higher; Baidu Shares Fall After Q3 Results
        Nov 21 PYXS Pyxis stock craters 46% amid Phase 1 data, William Blair downgrade
        Nov 21 BLRX BioLineRx inks licensing deal, share purchase agreement
        Nov 21 BLRX BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.
        Nov 20 PYXS Pyxis Oncology plummets 38% on preliminary phase 1 data for cancer asset
        Nov 20 PYXS Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data
        Nov 20 APTO Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy
        Nov 20 BLRX BioLineRx to Report Third Quarter 2024 Results on November 25, 2024
        Nov 20 HCWB HCW Biologics prices $6.9M registered direct offering at $1.03 per share
        Nov 19 HCWB HCW Biologics announces pricing of $6.9M registered direct offering, concurrent private placement
        Nov 19 HCWB HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules
        Nov 18 HCWB Top Midday Gainers
        Nov 18 HCWB Why Is Penny Stock HCW Biologics Surging On Monday?
        Nov 18 HCWB HCW Biologics jumps on license agreement for immunotherapeutic product candidate
        Nov 18 HCWB HCW Biologics and WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate
        Related Industries: Biotechnology
        Related Stock Lists: Acute Myeloid Leukemia Clinical Medicine Biopharmaceutical Cancer Medicine Solid Tumors Biotechnology Immunotherapy Cancer Treatment Immune System Immunology Immunotherapies Oncology Antineoplastic Drugs Autoimmune Disease Cancer Immunotherapy Cell Therapy Clinical Development Hematologic Malignancies Monoclonal Antibody
        Treatment Of Acute Myeloid Leukemia

        Acute myeloid leukemia (AML) is a type of cancer that affects the blood and bone marrow. Treatment for AML typically involves chemotherapy, radiation therapy, and/or stem cell transplantation. Depending on the type of AML, other treatments such as targeted therapy, immunotherapy, and/or clinical trials may also be recommended.

        Browse All Tags